Abstract
Cancer cell resistance to paclitaxel continues to be a major clinical problem. In this study, we utilized microRNA (miRNA) arrays to screen for differentially expressed miRNAs in paclitaxel-resistant cell lines established in vitro. We observed concordant upregulation of miR-135a in paclitaxel-resistant cell lines representing three human malignancies. Subsequently, the role of miRNA-135a was evaluated in an in vivo model of paclitaxel resistance. In this model, mice were inoculated subcutaneously with a non-small cell lung carcinoma cell line and treated with paclitaxel for a prolonged period. In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death. We further demonstrated a correlation between paclitaxel response and miR-135a expression in paclitaxel-resistant subclones that were established in vivo. The paclitaxel-resistant phenotype of these subclones was maintained upon retransplantation in new mice, as shown by decreased tumor response upon paclitaxel treatment compared with controls. Upregulation of miR-135a was associated with reduced expression of the adenomatous polyposis coli gene (APC). APC knockdown increased paclitaxel resistance in parental cell lines. Our results indicate that paclitaxel resistance is associated with upregulation of miR-135a, both in vitro and in vivo, and is in part determined by miR-135a-mediated downregulation of APC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anand S, Penrhyn-Lowe S, Venkitaraman AR . (2003). AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3: 51–62.
Aoki K, Taketo MM . (2007). Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci 120: 3327–3335.
Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z et al. (2007). MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 6: 1483–1491.
Chu Q, Vincent M, Logan D, Mackay JA, Evans WK . (2005). Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 50: 355–374.
Cleveland WS . (1979). Robust locally weighted regression and smoothing scatter plots. J Amer Statist Assoc 74: 829–836.
Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK . (2009). MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8: 1055–1066.
Dikovskaya D, Schiffmann D, Newton IP, Oakley A, Kroboth K, Sansom O et al. (2007). Loss of APC induces polyploidy as a result of a combination of defects in mitosis and apoptosis. J Cell Biol 176: 183–195.
Dombernowsky P, Gehl J, Boesgaard M, Paaske T, Jensen BV . (1996). Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 23: 23–27.
Esquela-Kerscher A, Slack FJ . (2006). Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259–269.
Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C et al. (2001). Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 3: 433–438.
Fong GH . (2008). Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis 11: 121–140.
Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A et al. (2010). MiR-148a attenuates paclitaxel-resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 25: 19076–19084.
Gelfand VI, Bershadsky AD . (1991). Microtubule dynamics: mechanism, regulation, and function. Annu Rev Cell Biol 7: 93–116.
Giles RH, van Es JH, Clevers H . (2003). Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1–24.
Goldie JH, Coldman AJ . (1979). A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733.
Greenberger LM, Lothstein L, Williams SS, Horwitz SB . (1988). Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci USA 85: 3762–3766.
Haldar S, Chintapalli J, Croce CM . (1996). Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253–1255.
He L, Hannon GJ . (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522–531.
Hoffman RM . (1991). Three-dimensional histoculture: origins and applications in cancer research. Cancer Cells 3: 86–92.
Huang G, Chen L . (2010). Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol 136: 1201–1211.
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065–7070.
Kaplan KB, Burds AA, Swedlow JR, Bekir SS, Sorger PK, Nathke IS . (2001). A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Nat Cell Biol 3: 429–432.
Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS . (1993). Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA 90: 3294–3298.
Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF et al. (2008). Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152–2159.
Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F et al. (2004). Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5: 91–102.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435: 834–838.
Mackler NJ, Pienta KJ . (2005). Drug insight: use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol 2: 92–100.
Mahon PC, Hirota K, Semenza GL . (2001). FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675–2686.
McGrogan BT, Gilmartin B, Carney DN, McCann A . (2008). Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785: 96–132.
Meads MB, Gatenby RA, Dalton WS . (2009). Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 9: 665–674.
Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M et al. (2008). The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE 3: e4029.
Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S et al. (2005). Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11: 298–305.
Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A et al. (2008). Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 68: 5795–5802.
Oguri T, Ozasa H, Uemura T, Bessho Y, Miyazaki M, Maeno K et al. (2008). MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther 7: 1150–1155.
Okugawa K, Kobayashi H, Hirakawa T, Sonoda T, Ogura T, Nakano H . (2004). In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo. J Cancer Res Clin Oncol 130: 178–186.
Patel N, Chatterjee SK, Vrbanac V, Chung I, Mu CJ, Olsen RR et al. (2010). Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proc Natl Acad Sci USA 107: 2503–2508.
Perkins C, Kim CN, Fang G, Bhalla KN . (1998). Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res 58: 4561–4566.
Pollard JW . (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71–78.
Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A et al. (2007). A comparison of background correction methods for two-colour microarrays. Bioinformatics 23: 2700–2707.
Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van de Wetering K et al. (2007). Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 104: 12117–12122.
Schiff PB, Fant J, Horwitz SB . (1979). Promotion of microtubule assembly in vitro by taxol. Nature 277: 665–667.
Shi J, Orth JD, Mitchison T . (2008). Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 68: 3269–3276.
Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C . (2008). Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111: 478–486.
Starling JJ, Maciak RS, Hinson NA, Hoskins J, Laguzza BC, Gadski RA et al. (1990). in vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates. Cancer Res 50: 7634–7640.
Sudo T, Nitta M, Saya H, Ueno NT . (2004). Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64: 2502–2508.
Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET et al. (2007). The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 67: 955–967.
Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW et al. (1990). Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247: 1457–1461.
Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM . (2006). cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat 96: 17–39.
Wakelee H, Ramalingam S, Belani CP . (2005). Docetaxel in advanced non-small cell lung cancer. Expert Rev Anticancer Ther 5: 13–24.
Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S et al. (2008). miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 123: 372–379.
Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K et al. (2005). Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature 434: 338–345.
Yang YH, Speed T . (2002). Design issues for cDNA microarray experiments. Nat Rev Genet 3: 579–588.
Zhang T, Otevrel T, Gao Z, Ehrlich SM, Fields JZ, Boman BM . (2001). Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61: 8664–8667.
Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y et al. (2010). MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1). J Biol Chem 285: 21496–21507.
Acknowledgements
We sincerely thank Dr John Heymach of MD Anderson Cancer Institute, Houston, TX and Jeremy Force, Children's Hospital Boston, for kindly providing us with the A549TR cells. This work was supported in part by grant CA37393 from the National Institutes of Health (BRZ), Kendle (AH), KWF Cancer Foundation (AH), the Stichting Fonds Catherine van Tussenbroek (AH), and a US Department of Defense PCRP fellowship (IC).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Holleman, A., Chung, I., Olsen, R. et al. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 30, 4386–4398 (2011). https://doi.org/10.1038/onc.2011.148
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.148
Keywords
This article is cited by
-
Synergistic killing effect of paclitaxel and honokiol in non-small cell lung cancer cells through paraptosis induction
Cellular Oncology (2021)
-
Decreased expression of FBXW7 by ERK1/2 activation in drug-resistant cancer cells confers transcriptional activation of MDR1 by suppression of ubiquitin degradation of HSF1
Cell Death & Disease (2020)
-
Tumor exosomes: a double-edged sword in cancer therapy
Acta Pharmacologica Sinica (2018)
-
High-throughput sequencing of pituitary and hypothalamic microRNA transcriptome associated with high rate of egg production
BMC Genomics (2017)
-
miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives
Targeted Oncology (2017)